Nu Skin Enterprises Toekomstige groei
Future criteriumcontroles 0/6
Nu Skin Enterprises zal naar verwachting groeien in winst en omzet met respectievelijk 136.5% en 0.6% per jaar. De winst per aandeel zal naar verwachting groeien met 136.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 8% zijn.
Belangrijke informatie
136.5%
Groei van de winst
136.6%
Groei van de winst per aandeel
| Personal Products winstgroei | 25.3% |
| Inkomstengroei | 0.6% |
| Toekomstig rendement op eigen vermogen | 8.0% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 22 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
The Market Doesn't Like What It Sees From Nu Skin Enterprises, Inc.'s (NYSE:NUS) Revenues Yet As Shares Tumble 27%
Oct 04
Nu Skin Enterprises' (NYSE:NUS) Returns On Capital Not Reflecting Well On The Business
Aug 31Insufficient Growth At Nu Skin Enterprises, Inc. (NYSE:NUS) Hampers Share Price
Aug 13Nu Skin Enterprises, Inc.'s (NYSE:NUS) CEO Might Not Expect Shareholders To Be So Generous This Year
May 30Is Nu Skin Enterprises (NYSE:NUS) Using Too Much Debt?
May 13Capital Allocation Trends At Nu Skin Enterprises (NYSE:NUS) Aren't Ideal
Mar 28Nu Skin: A Sell Signal Amidst Industry Decline And Strategic Uncertainty
Mar 04We Think You Can Look Beyond Nu Skin Enterprises' (NYSE:NUS) Lackluster Earnings
Feb 22Nu Skin Enterprises' (NYSE:NUS) Dividend Will Be Reduced To $0.06
Feb 19Analysts Just Shaved Their Nu Skin Enterprises, Inc. (NYSE:NUS) Forecasts Dramatically
Feb 18Nu Skin Enterprises, Inc. (NYSE:NUS) Could Be Riskier Than It Looks
Jan 18Nu Skin Enterprises (NYSE:NUS) Has A Somewhat Strained Balance Sheet
Dec 14Nu Skin Enterprises (NYSE:NUS) Has Affirmed Its Dividend Of $0.39
Nov 17Nu Skin: Is It Just A Growth Problem?
Oct 17Nu Skin Enterprises (NYSE:NUS) Could Be At Risk Of Shrinking As A Company
Oct 09When Should You Buy Nu Skin Enterprises, Inc. (NYSE:NUS)?
Sep 27Nu Skin: Attractive Valuation Trumps Near-Term Risks
Sep 12Nu Skin Enterprises (NYSE:NUS) Takes On Some Risk With Its Use Of Debt
Sep 08Nu Skin Enterprises (NYSE:NUS) Has Announced A Dividend Of $0.39
Aug 05Is Nu Skin Enterprises, Inc. (NYSE:NUS) Expensive For A Reason? A Look At Its Intrinsic Value
Jul 31Nu Skin: A High-Risk/High-Reward Turnaround Play Worth The Risks
Jun 26Is Now The Time To Look At Buying Nu Skin Enterprises, Inc. (NYSE:NUS)?
Jun 23We Think Nu Skin Enterprises (NYSE:NUS) Is Taking Some Risk With Its Debt
May 22Nu Skin Enterprises (NYSE:NUS) Will Pay A Dividend Of $0.39
May 07Nu Skin Enterprises (NYSE:NUS) Could Be Struggling To Allocate Capital
Apr 26Why Nu Skin Enterprises, Inc. (NYSE:NUS) Could Be Worth Watching
Mar 18Nu Skin Enterprises (NYSE:NUS) Will Pay A Larger Dividend Than Last Year At $0.39
Feb 19Nu Skin raises quarterly dividend by 1.3% to $0.39/share
Feb 15These 4 Measures Indicate That Nu Skin Enterprises (NYSE:NUS) Is Using Debt Reasonably Well
Feb 12Returns On Capital At Nu Skin Enterprises (NYSE:NUS) Paint A Concerning Picture
Jan 25Is Now The Time To Look At Buying Nu Skin Enterprises, Inc. (NYSE:NUS)?
Dec 04Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,887 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 1,798 | 52 | 46 | 116 | 3 |
| 12/31/2024 | 1,753 | -98 | 24 | 102 | 3 |
| 6/30/2024 | 1,844 | -148 | 107 | 160 | N/A |
| 3/31/2024 | 1,905 | -3 | 85 | 144 | N/A |
| 12/31/2023 | 1,969 | 9 | 60 | 119 | N/A |
| 9/30/2023 | 2,003 | 59 | 38 | 90 | N/A |
| 6/30/2023 | 2,042 | 70 | 2 | 67 | N/A |
| 3/31/2023 | 2,102 | 77 | 18 | 78 | N/A |
| 12/31/2022 | 2,226 | 105 | 49 | 108 | N/A |
| 9/30/2022 | 2,377 | 38 | 129 | 192 | N/A |
| 6/30/2022 | 2,480 | 113 | 142 | 194 | N/A |
| 3/31/2022 | 2,624 | 139 | 108 | 168 | N/A |
| 12/31/2021 | 2,696 | 147 | 73 | 142 | N/A |
| 9/30/2021 | 2,770 | 230 | 61 | 127 | N/A |
| 6/30/2021 | 2,833 | 237 | 143 | 215 | N/A |
| 3/31/2021 | 2,741 | 219 | 227 | 291 | N/A |
| 12/31/2020 | 2,582 | 191 | 315 | 379 | N/A |
| 9/30/2020 | 2,417 | 158 | 272 | 334 | N/A |
| 6/30/2020 | 2,304 | 146 | 204 | 270 | N/A |
| 3/31/2020 | 2,315 | 150 | 183 | 255 | N/A |
| 12/31/2019 | 2,420 | 174 | 112 | 178 | N/A |
| 9/30/2019 | 2,520 | 116 | 136 | 217 | N/A |
| 6/30/2019 | 2,606 | 125 | 154 | 225 | N/A |
| 3/31/2019 | 2,686 | 129 | 124 | 196 | N/A |
| 12/31/2018 | 2,679 | 122 | 132 | 203 | N/A |
| 9/30/2018 | 2,662 | 158 | 197 | 261 | N/A |
| 6/30/2018 | 2,550 | 146 | 210 | 270 | N/A |
| 3/31/2018 | 2,396 | 137 | N/A | 280 | N/A |
| 12/31/2017 | 2,279 | 129 | N/A | 303 | N/A |
| 9/30/2017 | 2,144 | 149 | N/A | 246 | N/A |
| 6/30/2017 | 2,185 | 165 | N/A | 223 | N/A |
| 3/31/2017 | 2,235 | 167 | N/A | 299 | N/A |
| 12/31/2016 | 2,208 | 143 | N/A | 275 | N/A |
| 9/30/2016 | 2,249 | 141 | N/A | 266 | N/A |
| 6/30/2016 | 2,216 | 100 | N/A | 298 | N/A |
| 3/31/2016 | 2,176 | 100 | N/A | 245 | N/A |
| 12/31/2015 | 2,247 | 133 | N/A | 322 | N/A |
| 9/30/2015 | 2,284 | 144 | N/A | 337 | N/A |
| 6/30/2015 | 2,352 | 196 | N/A | 288 | N/A |
| 3/31/2015 | 2,442 | 171 | N/A | 178 | N/A |
| 12/31/2014 | 2,569 | 189 | N/A | -56 | N/A |
| 9/30/2014 | 3,016 | 268 | N/A | -105 | N/A |
| 6/30/2014 | 3,285 | 311 | N/A | 156 | N/A |
| 3/31/2014 | 3,306 | 365 | N/A | 299 | N/A |
| 12/31/2013 | 3,177 | 365 | N/A | 530 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat NUS de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat NUS de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat NUS de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van NUS ( 0.6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.8% per jaar).
Hoge groei-inkomsten: De omzet van NUS ( 0.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen NUS zal naar verwachting over 3 jaar laag zijn ( 8 %).